Literature DB >> 20844995

Is rituximab superior to cyclophosphamide for ANCA-associated vasculitis for induction of remission, and with a better safety profile?

Ignacio Garcia-Valladares1, Luis R Espinoza.   

Abstract

Entities:  

Year:  2010        PMID： 20844995     DOI： 10.1007/s11926-010-0133-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  8 in total

1.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rachel B Jones; Alastair J Ferraro; Afzal N Chaudhry; Paul Brogan; Alan D Salama; Kenneth G C Smith; Caroline O S Savage; David R W Jayne
Journal:  Arthritis Rheum       Date:  2009-07

Review 2.  Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides.

Authors:  Ora Shovman; Boris Gilburd; Gisele Zandman-Goddard; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

3.  B cell abnormalities in Wegener's granulomatosis and microscopic polyangiitis: role of CD25+-expressing B cells.

Authors:  Per Eriksson; Christina Sandell; Karin Backteman; Jan Ernerudh
Journal:  J Rheumatol       Date:  2010-08-17       Impact factor: 4.666

4.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

Review 5.  New advances in the pathogenesis of ANCA-associated vasculitides.

Authors:  M Chen; C G M Kallenberg
Journal:  Clin Exp Rheumatol       Date:  2009 Jan-Feb       Impact factor: 4.473

6.  Wegener granulomatosis: an analysis of 158 patients.

Authors:  G S Hoffman; G S Kerr; R Y Leavitt; C W Hallahan; R S Lebovics; W D Travis; M Rottem; A S Fauci
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

Review 7.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

Review 8.  Granulomatous vasculitis.

Authors:  Javier Marquez; Diana Flores; Liliana Candia; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686
  8 in total
  2 in total

1.  Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.

Authors:  Evgeniy Evdoshenko; Alexey Maslyanskiy; Sergey Lapin; Leonid Zaslavsky; Ruth Dobson; Areg Totolian; Alexander Skoromets; Amit Bar-Or
Journal:  ISRN Neurol       Date:  2013-09-10

2.  Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

Authors:  Nicholas R Latimer; Christopher Carroll; Ruth Wong; Paul Tappenden; Michael C Venning; Raashid Luqmani
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.